Halozyme Therapeutics (NASDAQ:HALO) Releases FY24 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.55-3.90 for the period, compared to the consensus earnings per share estimate of $3.52. The company issued revenue guidance of $915-985 million, compared to the consensus revenue estimate of $954.43 million.

Halozyme Therapeutics Stock Up 4.4 %

Shares of Halozyme Therapeutics stock traded up $1.83 during trading on Thursday, hitting $43.84. 1,441,264 shares of the stock traded hands, compared to its average volume of 1,220,256. The company has a fifty day moving average price of $40.09 and a two-hundred day moving average price of $38.01. Halozyme Therapeutics has a twelve month low of $31.05 and a twelve month high of $45.00. The stock has a market cap of $5.57 billion, a P/E ratio of 19.91, a PEG ratio of 0.47 and a beta of 1.26. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The business had revenue of $230.04 million during the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Equities research analysts predict that Halozyme Therapeutics will post 3.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. JMP Securities reduced their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a market outperform rating for the company in a research report on Wednesday. TheStreet downgraded Halozyme Therapeutics from a b- rating to a c+ rating in a report on Monday, January 22nd. HC Wainwright restated a buy rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an outperform rating and a $54.00 target price on the stock. Finally, StockNews.com upgraded shares of Halozyme Therapeutics from a hold rating to a buy rating in a report on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $53.14.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 30,000 shares of company stock valued at $1,196,800. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.